I am a healthcare professional

Notice


Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.


Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.


By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.


Cookies


We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.


You can find out more about cookies by browsing our Privacy Policy.

 

For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Roche and Genentech at

ARVO 2023

-
Coming soon

Sign up or login to unlock the full suite of MEDICALLY features

Apr 28 / Roche and Genentech
Clustering and Treatment Patterns in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: A United States Claims Database Study
This poster presentation describes results from an observational study conducted using MarketScan claims databases of patients with nAMD and DME treated with anti-VEGF injection from Janurary- 1, 2017 - July 1, 2018 and followed for 2 years. Cluster analysis identified three groups within each disease that were separated by treatment characteristics. Payer and insurance type differed by cluster and may be associated with treatment patterns.

Sign up or login to unlock the full suite of MEDICALLY features

Personalised Healthcare
Apr 28 / Roche and Genentech
Relationship between Retinal Structural Abnormalities and Visual Outcomes in Diabetic Macular Edema: Phase 2 Boulevard Trial
Diabetic macula edema (DME) is the leading cause of vision loss among people with diabetes. Retinal structural abnormalities (key features of DME) can be detected using optical coherence tomography (OCT). However, the relationship between individual retinal structural abnormalities and visual function in eyes with DME is unclear. This study examines the relationship between retinal structural abnormalities and visual function in eyes with DME enrolled in the phase 2 BOULEVARD trial (NCT02699450).

Sign up or login to unlock the full suite of MEDICALLY features

Personalised Healthcare
Apr 28 / Roche and Genentech
Deep learning segmentation of foveal avascular zone (FAZ) in optical coherence tomography angiography (OCTA) of nonproliferative diabetic retinopathy
Diabetic retinopathy (DR) is a common complication of diabetes that can lead to vision loss if not adequately treated. DR progression can be monitored using optical coherence tomography angiography (OCTA) to identify changes in foveal vascular density (VD) and foveal avascular zone (FAZ) enlargement. Although automated FAZ measurements using OCTA device software are quicker than manual FAZ segmentation, they are not always reliable in eyes with DR and may require manual correction. This study examines whether FAZ area segmentation in OCTA with deep learning (DL) can be improved by adding supervised auxiliary tasks (FAZ boundary and/or retinal vessel mask).
12:45 PM
Duration 15mins La Nouvelle AB
Durable vision gains and greater fluid control with extended faricimab▼ dosing versus aflibercept in patients with diabetic macular edema
Lim J, Chen SJ, Steinle N, Jaffe G, Gerendas B, Abreu F, Camino A, Gibson K, Jain N, Shildkrot E, Souverain A, Tang Y, Willis J, Haskova Z

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
01:00 PM
Duration 15mins La Nouvelle AB
Faricimab▼ Reduces Macular Leakage vs Aflibercept in Patients With Diabetic Macular Edema
Goldberg R, Kolomeyer A, Nudleman E, Csaky K, Willis J, Gibson K, Wang T, Haskova Z, Shildkrot E, Amador M, Mar F

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
01:15 PM
Duration 15mins La Nouvelle AB
Faster time to retinal fluid control with faricimab▼ in patients with DME in the phase 3 YOSEMITE/RHINE trials
Pollreisz A, Camino A, Gibson K, Mar F, Shildkrot E, Tang Y, Willis J, Haskova Z

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
11:00 AM
Duration 15mins La Nouvelle AB
Port Delivery System With Ranibizumab in the Treatment of Diabetic Retinopathy Without Center-Involved Diabetic Macular Edema: Primary Analysis Results of the Phase 3 Pavilion Trial
Emanuelli A, Holekamp N, Latkany P, Brittain C, Quezada-Ruiz C, Howard D, Santhanakrishnan A, Wetzel-Smith M, Malhotra V, Pieramici D

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
03:30 PM
Duration 15mins La Nouvelle AB
Visual function loss in geographic atrophy: learnings from lampalizumab trial data
Steffen V, Anegondi N, Ferrara D, Chakravarthy U

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
10:45 AM
Duration 15mins La Nouvelle AB
Individualized faricimab▼ dosing up to every 16 weeks maintains robust anatomic and vision outcomes through 2 years in nAMD
Chaudhary V, Kotecha A, Willis J, Souverain A, Shildkrot E, Swaminathan B, Margaron P

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
11:30 AM
Duration 15mins La Nouvelle AB
A novel intravitreal anti-IL-6 monoclonal antibody for UME: preliminary results from the phase 1 DOVETAIL study
Sharma S, Suhler E, Lin P, Pauly-Evers M, Willen D, Peck R, Storti F, Rauhut S, Gott T, Passemard B, Macgregor L, Haskova Z, Silverman D, Fauser S, Mesquida M

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar